Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private label desloratadine coming

This article was originally published in The Tan Sheet

Executive Summary

Perrigo may launch a desloratadine anti-allergy product in July 2012 or sooner under circumstances outlined in a recent Hatch-Waxman litigation settlement, the Allegan, Mich.-based private labeler announced Dec. 4. The allergy product is equivalent to Schering-Plough's Clarinex 5 mg tablets, which Wolters Kluwer estimates sold $300 million in the 12 months ending October 2008, Perrigo says. The firm says it may launch the product as a prescription or OTC product depending on its status at the time of the launch

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel